STOCKS TELEGRAPH

Tag: AVXL

  • Here’s why Anavex Life Sciences Corp. (AVXL) Stock Sinking in Early Trading

    Here’s why Anavex Life Sciences Corp. (AVXL) Stock Sinking in Early Trading

    Anavex Life Sciences Corp. (AVXL) is a leading biotherapeutics company engaged in the development of therapeutics for neurodegenerative and neurodevelopmental disorders. The pipeline candidate ANAVEX 2-73 is used in Alzheimer’s and Parkinson’s disease along with dementia and Rett syndrome. ANAVEX 3-71 is used in Alzheimer’s treatment along with mitochondrial dysfunction and neuroinflammation.

    The price of AVXL stock during the regular trading on February 1, 2022, was last checked to be $10.75 with a 17.81% decline.

    AVXL: Events and Happenings

    On February 01, 2022, AVXL announced hopeful top-line outcomes in Phase 3 trials of ANAVEX 2-73 for treating Rett syndrome. The company also established a statistical development for the primary and secondary efficacy endpoint.

    AVXL: CEO Comments

    Speaking at the momentous occasion, the company’s CEO Christopher U Missling stated that the Phase 3 trials of ANAVEX®2-73 build on its potential to validate the meaningful developments in disease. He further added that the company is looking forward to continuing its successful journey.

    On January 10, 2022, AVXL reported optimistic top-line outcomes from ANAVEX 3-71 Phase 1 clinical trial. The trials were performed for the Frontotemporal Dementia disorder.

    On January 05, 2022, AVXL announced that the Executives presented at the H.C. Wainwright Virtual BioConnect 2022 Conference on January 10-13, 2022. On December 14, 2021, AVXL reported that the company’s management participated at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022. On November 29, 2021, AVXL announced that the company’s Executives participated at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021.

    AVXL: Key Financials

    On November 24, 2021, AVXL reported its financial results for the fiscal year ended September 30, 2021. Some of the key highlights are as follows.

    Assets

    Total assets of the company in fiscal 2021 were recorded to be $161.6 million.

    Net Loss per Share

    Basic and diluted net loss per share in fiscal 2021 was $37.9 million, or $0.54 compared with $26.3 million or $0.45 in the same period of 2020.

    AVXL announced on November 10, 2021, about the company’s management participation at the Lausanne VIII Workshop on November 17, 2021.

    Conclusion

    AVXL stock performance was not good during the last month as it dipped by 26%. The current decline in early trading is likely attributed to the recently issued positive primary and secondary endpoints outcomes. The financial experts are hoping that the company’s stock will bounce back to good shape in a shorter duration of time.

  • The 3 Best Pharmacy Stocks for long-term Investment

    The 3 Best Pharmacy Stocks for long-term Investment

    The pharma industry has been a long-term investment opportunity for investors over the years.

    The global pharmaceutical industry is a massive market that continues to grow each year. It is estimated to be more than $1.2 trillion in sales annually. The COVID-19 pandemic has been a massive catalyst in pushing pharma firms to their limit. The majority of the companies have tried their luck in developing the coronavirus vaccine—with several being successful and others under clinical trials.

    For investors, the pharmacy stocks have the potential to reap solid long-term results—with a broader market. Especially, with the demand for vaccines high all over the world, the pharma stocks could be making big profits in the future. So, let’s have a look at the three best pharma stocks for long-term investment.

    Pfizer (PFE)

    Pfizer (PFE) has been the highlight of last year. The US-based pharma firm was the first—in collaboration with BioNTech—to develop the COVID-19 vaccine. Despite the vaccine news, the stock price hasn’t skyrocketed as it was expected. So, there is much upside considering the stock being backed by Pfizer’s vaccine and other top-line products.

    Recently, the company reported its fourth-quarter results, with earnings on the lower side as per the expectations. The Q4 2020 adjusted earnings were $0.42 per share, topping by 14% Year-over-Year but missing analysts’ estimate of $0.51 per share. While, the sales increased by 12% to $11.68 billion, missing projected sales of $12.01 billion.

    Mizuho Securities analyst Vamil Divan said that the company has multiple parts under movement, but the long-term seems strong with its core assets performing well. Pfizer has reportedly said that they are expecting $15 billion of vaccine sales this year. So far, the company has vaccine sales of around $154 million.

    With much happening, Pfizer (PFE) stock is still in the buy range.

    Bristol-Myers (BMY)

    Bristol Myers Squibb (BMY) is one of the leading pharmaceutical firms in biologics in several therapeutic areas, including cancer. The company is set to release its fourth-quarter results on Feb. 4, 2021.

    According to Forbes, the overall outcome is expected to be slightly on the lighter side as per the analysts’ estimate. The quarterly results are affected by a slow sales growth rate of Opdivo. However, the company should see an increase in overall demand due to a rise in hospital visits.

    The company has announced that it has obtained positive outcomes from the second pivotal Phase 3 trial for its novel, oral, POETYK PSO-2. Bristol is working on selective tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis—patients with moderate to severe disease. Almost 100 million people are suffering from psoriasis around the world. If the company goes on to successfully market its product, it would bring massive revenue in the longer run.

    Furthermore, Bristol Myers Squibb (BMY) has collaborated with The Rockefeller University for the rights to a Covid-19 therapy that combines two antibodies. The company stated that the vaccine variant of Rockefeller has delivered effective results against SARS-CoV-2. So, this deal could be another big plus for Bristol as we head forward.

    Anavex (AVXL)

    Anavex Life Sciences (AVXL) is a promising biopharma firm that has gained a lot of attention for its lead candidate of Alzheimer’s disease, Anavex 2-73 (A2-73). Recently, the company updated that it has completed 80enrollment for the Phase 2b/3 trials. While the remaining enrollment of 450 patients is anticipated in near-future.

    Over the past 12-months, AVXL shares have soared over 163%. As of Feb. 4, in pre-market trading, the stock is up by nearly 87% trading around $19.67. The bullish sentiment is pushed by the lead drug of Anavex.

    So far, the data shows that Anavex 2-73 is very effective against Alzheimer’s disease. According to World Health Organization, more than 50 million suffer from dementia—a type of Alzheimer—all over the world. And, around 10 million new cases arise each year.

    Being bullish on Anavex, Seeking Alpha’scontributor Lane Simonian stated that Anavex 2-73 has the best chance of long-term success among the rest of the drugs being studied by the company. So, Anavex (AVXL) is a stock to watch for long-term investment.